About this item:

532 Views | 342 Downloads

Author Notes:

Address correspondence to Joanna B. Goldberg, joanna.goldberg@emory.edu.

Reviewed by Stephen Lory, Solicited external reviewer and Daniel Wozniak, Solicited external reviewer.

We thank Jeffrey Meisner for purification of Wzz2 and construction of mini-CTX-optRBS-lacZ and Dominique Limoli for the isolation of CFBRPA32 and CFBRPA43 nonmucoid revertants.

Clinical isolates were obtained from the Cystic Fibrosis Biospecimen Registry (CFBR), which is maintained by Emory University and the Children’s Healthcare of Atlanta Center for Cystic Fibrosis and Airways Disease Research (CF-AIR).

Subjects:

Research Funding:

This work was partially supported by a predoctoral fellowship to A.R.C. from the Cystic Fibrosis Foundation (CFF)-funded CF@LANTA RDP Center (MCCART15R0), CF-AIR, components of the Emory+Children’s CF Center of Excellence at Emory University, and Children’s Healthcare of Atlanta.

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award number F31AI136310 also supported A.R.C.

Additional funding was awarded by the NIH and the CFF to J.B.G. under award numbers R21AI122192 and GOLDBE16G0, respectively.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Microbiology
  • Pseudomonas aeruginosa
  • alginate
  • lipopolysaccharide
  • DNA-BINDING PROTEIN
  • TRANSPOSON MUTANT LIBRARY
  • CYSTIC-FIBROSIS
  • ALGINATE PRODUCTION
  • CHAIN-LENGTH
  • SIGMA-FACTOR
  • FLAGELLUM BIOSYNTHESIS
  • RESPONSE REGULATOR
  • NTRC FAMILY
  • EXPRESSION

Remodeling of O Antigen in Mucoid Pseudomonas aeruginosa via Transcriptional Repression of wzz2

Tools:

Journal Title:

mBio

Volume:

Volume 10, Number 1

Publisher:

, Pages e02914-18

Type of Work:

Article | Final Publisher PDF

Abstract:

Pseudomonas aeruginosa is an opportunistic pathogen that causes chronic lung infections in people with cystic fibrosis (CF). Chronic P. aeruginosa isolates generally do not express O antigen and often have a mucoid phenotype, which is characterized by the overproduction of the exopolysaccharide alginate. Therefore, O antigen expression and the mucoid phenotype may be coordinately regulated upon chronic adaption to the CF lung. Here we demonstrate that PDO300, a mucoid strain derived from the nonmucoid laboratory isolate PAO1, does not produce very long O antigen due to decreased expression of Wzz2, the very long O antigen chain length control protein, and that mucoid clinical isolates express reduced levels of Wzz2 compared to nonmucoid isolates. Further, we show that forcing the expression of very long O antigen by PDO300, by providing wzz2 in trans, does not alter alginate production, suggesting that sugar precursors are not limited between the two biosynthesis pathways. Moreover, we confirm that AmrZ, a transcription factor highly expressed in mucoid strains, is a negative regulator of wzz2 promoter activity and very long O antigen expression. These experiments identify the first transcriptional regulator of O antigen chain length in P. aeruginosa and support a model where transition to a chronic mucoid phenotype is correlated with downregulation of very long O antigen through decreased Wzz2 production. IMPORTANCE Detection of mucoid Pseudomonas aeruginosa, characterized by the overproduction of alginate, is correlated with the establishment of a chronic pulmonary infection and disease progression in people with cystic fibrosis (CF). In addition to the overproduction of alginate, loss of O antigen lipopolysaccharide production is also selected for in chronic infection isolates. In this study, we have identified the regulatory network that inversely regulates O antigen and alginate production. Understanding the regulation of these chronic phenotypes will elucidate mechanisms that are important for the establishment of a long-term P. aeruginosa lung infection and ultimately provide an opportunity for intervention. Preventing P. aeruginosa from chronically adapting to the CF lung environment could provide a better outcome for people who are infected.

Copyright information:

© 2019 Cross and Goldberg.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote